
CLAIMS


1. Use of a compound represented by formula (**II**)



(**II**)

in the manufacture of a medicament for treating or preventing preterm labor in a human patient, wherein the compound is to be provided to the patient with an additional therapeutic agent.

2. Use of a compound represented by formula (**II**)



(**II**)

in the manufacture of a medicament for preventing labor prior to cesarean delivery in a human patient, wherein the compound is to be provided to the patient with an additional therapeutic agent.

3. The use of claim 1 or 2, wherein said additional therapeutic agent is an additional tocolytic agent.

4. The use of claim 3, wherein the tocolytic agent is an oxytocin receptor antagonist.

5. The use of claim 4, wherein said oxytocin receptor antagonist is atosiban, retosiban, barusiban, epelsiban, or nolasiban.

6. The use of claim 3, wherein the tocolytic agent is a calcium channel inhibitor.

7. The use of claim 6, wherein the calcium channel inhibitor is nifedipine or nicardipine.

8. The use of claim 1 or 2, wherein the additional therapeutic agent is a betamimetic, a magnesium salt, a nitric oxide donor, progesterone or a variant thereof, or a corticosteroid.

9. The use of claim 1 or 2, wherein the additional therapeutic agent is a betamimetic selected from the group consisting of terbutaline, ritodrine, hexoprenaline, albuterol, fenoterol, nylidrin, and orciprenaline.

10. The use of claim 1 or 2, wherein the additional therapeutic agent is magnesium sulfate.

11. The use of claim 1 or 2, wherein the additional therapeutic agent is nitroglycerine.

12. The use of claim 1 or 2, wherein the additional therapeutic agent is progesterone or 17-α-hydroxyprogesterone caproate.

13. The use of claim 1 or 2, wherein said corticosteroid is selected from the group consisting of betamethasone, dexamethasone, and hydrocortisone.

14. The use of claim 1 or 2, wherein the patient is characterized by a gestational age of from about 24 weeks to about 34 weeks.